Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

256.46 -3.75 (-1.44%)

Official Closing Price Updated: 7:00 PM EDT, Sep 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗

Today 8:50 EDT

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

Via MarketBeat

Topics Artificial Intelligence Bonds

3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King) ↗

September 05, 2026

Owning these dividend stocks could be a simple way to make money over the long term.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 04, 2026

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

Via The Motley Fool

Topics Intellectual Property

True Beauty Aesthetics Marks One-Year Milestone With Open House

September 02, 2026

MOUNT PLEASANT, SC - September 02, 2026 - Malissa LaRoche, PA-C, owner of True Beauty Aesthetics, is celebrating one year at the practice's current Mount Pleasant location this month, with...

Via Press Advantage

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 29, 2026

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

Via The Motley Fool

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 29, 2026

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

Via The Motley Fool

If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today ↗

August 26, 2026

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.74% on an annualized basis producing an average annual return of 15.14%. Currently, AbbVie has a market capitalization of...

Via Benzinga

Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy. ↗

August 26, 2026

His AbbVie purchase was a big move into a high-yielding dividend stock.

Via The Motley Fool

2 S&P 500 Stocks with Exciting Potential and 1 We Brush Off

August 25, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

Via StockStory

Topics Electric Vehicles Stocks World Trade

Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead. ↗

August 24, 2026

AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

Via The Motley Fool

Topics Intellectual Property

2 Dividend Stocks to Buy and Never Sell ↗

August 23, 2026

Both of these healthcare leaders are Dividend Kings.

Via The Motley Fool

Topics Economy

The Dividend ETF That Generates Passive Income While You Sleep ↗

August 21, 2026

Income generation is more about finding consistency than finding an ultra-high yield.

Via The Motley Fool

Topics ETFs

August 21, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

Topics Energy

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗

August 20, 2026

Don't bet against Vertex Pharmaceuticals in cystic fibrosis.

Via The Motley Fool

Plastic Surgeon Dr. Young Cho Named to National MD Codes Faculty

August 19, 2026

August 19, 2026 - Integrated Aesthetics announced that board-certified plastic surgeon Young Cho, MD, PhD, has been selected as a national trainer in the MD Codes™ program within the Allergan...

Via Press Advantage

Billionaire Ken Griffin Increased His Position in This Dividend King by 547% ↗

August 19, 2026

Ken Griffin sees a bargain in Abbvie and increased his fund's position by buying 2.68 million shares of the healthcare giant.

Via The Motley Fool

Topics Intellectual Property

A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.

August 18, 2026

From Equity Insider

Via GlobeNewswire

2 Dividend Stocks That Are No-Brainer Buys in August ↗

August 18, 2026

They have businesses built to handle the toughest environments.

Via The Motley Fool

Topics Economy Intellectual Property

Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year ↗

August 16, 2026

AbbVie has another blockbuster business emerging.

Via The Motley Fool

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗

August 14, 2026

The drugmaker should significantly mitigate its most important risk as it develops new products.

Via The Motley Fool

AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 14, 2026

Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.

Via The Motley Fool

Topics Intellectual Property

The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For

August 12, 2026

News Provided by USA News Group on behalf of Conexeu Sciences Inc.

From USA News Group

Via GlobeNewswire

2 Reasons to Like ABBV and 1 to Stay Skeptical

August 12, 2026

AbbVie has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.7% to $249.64 per...

Via StockStory

Topics Stocks Supply Chain

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 11, 2026

AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.

Via The Motley Fool

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026? ↗

August 11, 2026

Both of these stocks pay more than double the S&P 500 average of 1.1%.

Via The Motley Fool

Topics Stocks

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry? ↗

August 11, 2026

The pharmaceutical company hopes that another big-time acquisition will pay off.

Via The Motley Fool

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings? ↗

August 10, 2026

The stock is up just 8% this year and could prove to be an undervalued buy.

Via The Motley Fool

Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026? ↗

August 08, 2026

XLV's concentrated 60-stock portfolio beat VHT's broader 423 holdings over five years, though VHT delivered stronger 1-year returns.

Via The Motley Fool

Topics ETFs Economy

MarketBeat Week in Review – 08/03 - 08/07 ↗

August 08, 2026

A weekly roundup of MarketBeat analysis covering earnings from AbbVie, AMD, Palantir, Meta, Reddit, SpaceX and others, plus upcoming CPI and PPI inflation data.

Via MarketBeat

Topics Economy Intellectual Property

AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 07, 2026

AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.